MeSH definition : A type of ALPHAPAPILLOMAVIRUS especially associated with malignant tumors of the CERVIX
and the RESPIRATORY MUCOSA.;
MeSH synonym : hpv 16; HPV-16; HPV16; HPV16s; human papillomavirus type 16 HPV16; Human papillomavirus type 16; Human papillomavirus - 16; human papillomavirus type 16 HPV 16; HPV 16s;
CISMeF synonym : papillomavirus 16, human;
MeSH annotation : infection: coordinate IM with PAPILLOMAVIRUS INFECTIONS (IM) UTERINE CERVICAL NEOPLASMS
(IM), RESPIRATORY TRACT NEOPLASMS (IM) or other neoplasm term (IM) if pertinent; infection: coordinate with PAPILLOMAVIRUS INFECTIONS UTERINE CERVICAL NEOPLASMS,
RESPIRATORY TRACT NEOPLASMS or other neoplasm term if pertinent;
A type of ALPHAPAPILLOMAVIRUS especially associated with malignant tumors of the CERVIX
and the RESPIRATORY MUCOSA.
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69604608 2012 France summary of product characteristics package leaflet human papillomavirus 11 suspensions papillomavirus vaccines human papillomavirus 16 syringes human papillomavirus 6 injections
--- https://www.has-sante.fr/portail/jcms/c_464141/fr/evaluation-de-l-interet-de-la-recherche-des-papillomavirus-humains-hpv-dans-le-depistage-des-lesions-precancereuses-et-cancereuses-du-col-de-l-uterus 2004 false false Haute Autorité de santé France French papillomavirus infections papillomavirus infections practice guidelines as topic bibliography of medicine uterine cervical neoplasms uterine cervical neoplasms mass screening precancerous conditions mass screening france mass screening genetic testing uterine cervical neoplasms uterine cervical neoplasms incidence papillomavirus infections prevalence age factors vaginal smears vaginal smears precancerous conditions colposcopy predictive value of tests risk algorithms consensus development conferences as topic socioeconomic factors public health guidelines mass screening uterine cervical neoplasms uterine cervical neoplasms risk factors sensitivity and specificity costs and cost analysis human papillomavirus 16 human papillomavirus 18 economic evaluation health technology assessment treatment outcome